- Respiratory eHealth company Adherium (ADR) signs its first UK distribution deal with Helicon Health to sell the Hailie sensor range and cloud data services
- Helicon Health is a medical technology company that delivers technological innovations for the virtual delivery of healthcare
- The Hailie platform attaches to an asthma or chronic obstructive pulmonary disease (COPD) medication inhaler and connects to Helicon’s remote patient monitoring platform
- It was designed to provide visibility to healthcare providers of a patient’s medication use to better understand patterns in disease
- Adherium has ended the day in the grey with shares trading at 0.7 cents
Respiratory eHealth company Adherium (ADR) has signed its first UK distribution deal with Helicon Health to sell the Hailie sensor range and cloud data services.
Helicon Health is a medical technology company, specialised medical device accelerator and NHS-focused contract research partner.
It delivers technological innovations for the virtual delivery of healthcare, partners with innovators to create new technologies and engineers solutions to deliver transformations in healthcare.
Helicon currently offers virtual solutions and support for dementia, diabetes, cancer, cardiovascular disease, neo natal and trauma.
“This agreement with Adherium marks yet another milestone in our journey towards helping people live longer healthier lives,” Helicon CEO Tony Bowden said.
“Supporting people with understanding and complying with the instructions for use of medications is fundamental to achieving the healthcare outcomes people young and old and all in between need — whilst at the same time helping health systems gain the best results from scarce resources.”
The Hailie platform provides clinicians, healthcare providers and patients access to remotely monitor medication usage guidelines.
It attaches to an asthma or chronic obstructive pulmonary disease (COPD) medication inhaler and connects to Helicon’s remote patient monitoring platform.
It was designed to provide visibility to healthcare providers of a patient’s medication use to better understand patterns in disease.
“This agreement with Helicon presents a significant opportunity to better serve the often overlooked severe Asthma population and give a true and metric-driven care pathway for
COPD patients,” Adherium Global VP Business Development Francis White said.
“The expertise of the team at Helicon will transform our market access in the UK, give us opportunities in ground-breaking care and accelerate adoption.”
Adherium has ended the day in the grey with shares trading at 0.7 cents.